RELIEVE IBS-D
Double-blind, randomised, placebo-controlled trial in 440 adults with IBS-D at 28 UK sites. Chief Investigator: Prof Yan Yiannakou.
Yes. ENTEROSGEL has been studied in randomised clinical trials in adults, children and people with IBS-D, and in laboratory studies, published in GUT, BMJ journals and Scientific Reports.
Double-blind, randomised, placebo-controlled trial in 440 adults with IBS-D at 28 UK sites. Chief Investigator: Prof Yan Yiannakou.
Randomised trial in 105 adults with acute diarrhoea in UK GP practices: ENTEROSGEL with rehydration versus rehydration alone. Investigator: Dr Preeti Pandya.
Randomised feasibility study in 50 children aged 6–59 months in The Gambia, led by Prof Stephen Allen. ENTEROSGEL was mixed straight into ORS.
In vitro study of what the gel binds: bacterial toxins (E. coli endotoxin, Shigella and C. difficile toxins) and excess bile acids.
The largest trial of an intestinal adsorbent in IBS-D. ENTEROSGEL relieved the global symptoms of IBS-D and improved quality of life, which is why it is now named a first-line option in The Lancet Gastroenterology & Hepatology (2024).
In a laboratory study at Imperial College London, ENTEROSGEL adsorbed key inflammatory molecules within 15 minutes under the reported conditions.
ENTOPIC is a UK randomised, double-blind, placebo-controlled trial of ENTEROSGEL for functional abdominal pain disorders in children aged 3–18, assessing pain, gut symptoms and quality of life. These conditions affect more than 1 in 9 children worldwide.
Yes. ENTEROSGEL has been tested in three randomised clinical trials, in adults with IBS-D (440 patients, GUT 2022), adults with acute diarrhoea (BMJ Open Gastroenterology 2019) and young children with acute diarrhoea (BMJ Paediatrics Open 2025), and in laboratory studies published in Scientific Reports.
In this double-blind, placebo-controlled trial of 440 adults at 28 UK sites, ENTEROSGEL relieved the global symptoms of IBS-D, including diarrhoea, urgency, bloating and abdominal pain, and improved quality of life. 76% reported adequate relief in the open-label phase.
Yes. A 2024 review on personalising IBS treatment in The Lancet Gastroenterology & Hepatology named ENTEROSGEL as a first-line option for IBS-D where diarrhoea and urgency dominate.
It is an oral intestinal adsorbent. Laboratory studies show it binds bacterial toxins, excess bile acids and inflammatory molecules, while binding far less of the medicines tested than activated charcoal. It is not absorbed into the blood.
Yes. It was well tolerated in the adult and children’s trials of acute diarrhoea and in the RELIEVE IBS-D trial.
Yes. ENTOPIC (ISRCTN16474818) is a UK randomised, double-blind, placebo-controlled trial of ENTEROSGEL in children with functional abdominal pain disorders.
The 225 g tube and 4-week IBS-D course, travel sachets and Kids 0+: the same gel tested in the trials.
Research briefing, samples and patient leaflets for your practice or pharmacy.